Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells

Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells

Glioblastoma Multiforme (GBM) tumors contain a small population of glioma stem-like cells (GSCs) among the various differentiated GBM cells (d-GCs). GSCs drive tumor recurrence, and resistance to Temozolomide (TMZ), the standard of care (SoC) for GBM chemotherapy. In order to investigate a potential...

Full description

Bibliographic Details
Main Authors: Sandipan Datta, Thomas Sears, Gino Cortopassi, Kevin Woolard, James M. Angelastro
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Glioblastoma multiforme
Mitochondria
Chemotherapy
Cancer stem cells
Drug repurposing
Therapeutics
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332220312506

Similar Items

Similar Items